# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Fannie Lou Hamer (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML031-SYN
- Date: 2026-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Batiste-Hill, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Seven-month review: A1c, urine albumin, kidney function, seasonal and age-50 vaccines, screening results, and plans for the winter. **S**

## History of present illness

Mrs. Hamer returns five weeks after her preventive visit; she turned 50 this month. Her mammogram two weeks ago showed no abnormality, and her stool test, HIV and hepatitis C tests were negative. She went to the mammogram with the community health worker and said the technologist explained every step. Her home readings average 126/78. She takes metformin 1,500 mg with her evening meal without stomach trouble and has had no low blood sugar. Food and heating are covered for the winter, and the van has brought her to every visit. She asked about the vaccines due this autumn and what each one is for. **S**

| Element | Detail |
|---|---|
| Screening | Mammogram normal; stool test, HIV and hepatitis C negative |
| Home blood pressure | Average 126/78 |
| Metformin | 1,500 mg, well tolerated |
| Vaccines | Influenza, COVID-19 and zoster discussed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight gain |
| Cardiovascular | Negative | No ankle swelling |
| Gastrointestinal | Negative | No stomach upset |
| Genitourinary | Negative | No burning or genital itching |
| Psychiatric | Negative | Mood steady |

5 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg oral tablet, three tablets with the evening meal **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 90 kg; BMI 33.9 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 6.9% (high); Urine albumin-to-creatinine ratio: 41 mg/g (high); Potassium: 4.5 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 69 mL/min/1.73 m² (low); AHC-HRSN screen: core needs positive (0 to 5): 1. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 8.6% (high) at baseline, 6.9% (high) at this visit **S**
- Urine albumin-to-creatinine ratio: 88 mg/g (high) at baseline, 41 mg/g (high) at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 1 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 73 mL/min/1.73 m² (low) at baseline, 69 mL/min/1.73 m² (low) at this visit **S**
- AHC-HRSN screen: core needs positive (0 to 5): 3 at baseline, 1 at this visit **S**

## Immunizations given today

- Influenza vaccine, inactivated, this season **S**
- COVID-19 vaccine, mRNA, this season **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Consent and chaperone | Each vaccine, the blood draw, urine sample and examination explained and agreed; she accepted all three vaccines; female nurse present |
| General | Well; blood pressure 124/76, pulse 74; weight 90.0 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Feet | Inspected with her agreement: no ulcers |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes** (E11.65). A1c 6.9%: at goal, without low blood sugar. **S**
   - Continue metformin 1,500 mg and dapagliflozin.
   - A1c every six months now that she is at goal.
   - Comprehensive foot examination and vitamin B12 at the one-year visit.
2. **Chronic kidney disease G2 A2** (N18.2). Urine albumin-to-creatinine ratio 41 mg/g, down by more than half from 96 but still moderately increased; potassium 4.5 mmol/L; creatinine 1.00 mg/dL, eGFR 69. **S**
   - Telehealth review with Dr. Agbaje in the new year about further kidney protection, as the consultation planned.
   - Urine albumin and kidney function every six months.
3. **Hypertension with chronic kidney disease** (I12.9). At goal: 124/76 in the clinic, 126/78 at home. **S**
   - Continue amlodipine-benazepril.
4. **Transportation insecurity** (Z59.82). Rides booked for every visit; other trips still uncertain; winter plan made. **S**
   - Phone visits if roads or rides fail in winter; 90-day medicine supplies.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Consent and chaperone for every examination, test and procedure | Every visit | Completed today | Each vaccine and test explained and agreed |
| Examination | Clinic blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 124/76 |
| Self-management | Home blood pressure readings | Seven days to confirm the diagnosis; then twice a week, and daily for a week after any change | Completed today | Average 126/78 |
| Examination | Weight and BMI | Every visit | Completed today | 90.0 kg, down 3 kg since intake |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal, then every 6 months | Completed today | 6.9% |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; 3 to 6 months after a treatment change; then every 6 months while moderately increased | Completed today | 41 mg/g |
| Laboratory | Potassium, creatinine and eGFR | One to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes) | Completed today | Potassium 4.5 mmol/L; creatinine 1.00 mg/dL, eGFR 69 |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 80 in May; yearly panel at one year |
| Imaging | Diabetic eye examination (retinal photographs) | At diagnosis, then every 1 to 2 years if no retinopathy | Up to date | No retinopathy in May |
| Examination | Foot inspection, and comprehensive foot examination | Inspection every visit; comprehensive examination yearly | Completed today | Inspection normal; comprehensive examination due at one year |
| Laboratory | Vitamin B12 on metformin | Periodically, about yearly | Due | At the one-year visit |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and cost | Every visit | Completed today | No side effects; 90-day supplies arranged for winter |
| Medication safety | Influenza, COVID-19 and recombinant zoster vaccines | Influenza and COVID-19 each autumn; zoster from 50, two doses 2 to 6 months apart | Completed today | All three given after she agreed; zoster dose 2 in two to six months |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 to 12 months | Up to date | PHQ-9 3 three months ago; PHQ-2 0 at the preventive visit |
| Survey | Social needs screen (AHC-HRSN) and resources | At intake, then every few months while needs are open | Completed today | One core need positive (transportation on some days) |
| Referral | Nephrology review | At diagnosis; then by telehealth if albumin stays raised | Due | Telehealth review in the new year because albumin remains moderately increased |

## Goal progress

- Every examination, test and procedure explained first and done only with her documented agreement, with a chaperone of her choosing, at every visit. Outcome by 2026-10-19: Consent documented for every examination, blood draw, ultrasound, photograph, vaccine and screening test; she declined a breast and a pelvic examination, and that was respected. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home within six months. Outcome by 2026-10-19: 124/76 in the clinic; home average 126/78. **S**
- A1c below 7% within six to nine months, without low blood sugar. Outcome by 2026-10-19: 6.9% at seven months; no low blood sugar. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. Outcome by 2026-10-19: 88 to 96 mg/g at baseline; 41 mg/g at seven months. **S**
- Food and utility needs met through benefits, and a dependable way to reach every visit and laboratory test. Outcome by 2026-10-19: SNAP and energy assistance in place; rides arranged for every visit after one missed laboratory check; transportation still uncertain on some days. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-10-19: 146 to 80 mg/dL on atorvastatin; recheck with the yearly panel. **S**

## Guideline basis

- Introduction and Methodology: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026), Aether Forge
- Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014), Substance Abuse and Mental Health Services Administration
- Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026), American Medical Association
- The Accountable Health Communities Health-Related Social Needs Screening Tool (2017), Centers for Medicare & Medicaid Services
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Telehealth nephrology review in the new year. Review in three months, or by phone if travel fails; second zoster dose in two to six months. Call for dizziness, vomiting that stops her drinking, or any new symptom. **S**

